Daily notes / October 16, 2026

Himanshu H. Shah filed a Schedule 13D/A on Novavax

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 16, 2026. Published October 17, 2026. 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers. — Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Himanshu H. Shah filed a Schedule 13D/A on Oct 16, 2026, reporting 10,656,964 shares, or 6.46% of Novavax (NVAX). The filing came 71 days after Novavax’s Aug 6, 2026 results announcement. It reports ownership, but does not say when shares were bought.

What did Himanshu H. Shah report?

The SEC Schedule 13D shows that Himanshu H. Shah filed a Schedule 13D/A on Oct 16, 2026. The filing reports 10,656,964 shares, representing 6.46% of the class of Novavax (NVAX).

The filing is an ownership report. It does not identify a purchase date for the reported shares.

How does the filing relate to Novavax’s results announcement?

The Schedule 13D/A was filed 71 days after Novavax announced results on Aug 6, 2026, in an 8-K Item 2.02. The timing places the ownership filing after that company announcement, but does not establish a connection between them.

What other ownership and market records are available?

In Schedule 13D and 13G filings on Novavax during the 180 days to Oct 16, 2026, Himanshu H. Shah is described as owning 6.5% of NVAX as a passive investor, with the filing dated Oct 16, 2026. The pack also reports FINRA short interest of 46,046,946 shares on the settlement date of Sep 30, 2026, down -7.68% on the previous report and about 8.06 days of average volume.

For the quarter ended Jun 30, 2026, 13F filings listed Jupiter Asset Management Ltd and OP Asset Management Ltd as the largest positions that grew, both marked as new positions. Caxton Associates LLP and Allianz SE were the largest positions that shrank, both marked as sold out. A 13F is a quarter-end snapshot and has no trade date.

What was reported around the filing date?

NVAX closed at $11.26 on Oct 16, 2026, the last session on or before the filing date. From Sep 16, 2026 to Oct 16, 2026, the close moved from $9.35 to $11.26, a change of +20.4%. These prices are context, not an explanation of the ownership report.

Finnhub listed the headline “Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know” from Yahoo on Oct 16, 2026. It also listed “Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady” from Yahoo on Oct 16, 2026. The headlines are listed as published by the outlets; OQRO has not checked them and does not summarise the articles. See Novavax on OQRO for the company page.

What this does not tell you?

A Schedule 13D or 13G is an ownership filing, not a trade, and does not say when shares were bought. The filing does not explain share-price moves; other news can move a price. The price information is listed as context only.

This article describes public filings and is not investment advice.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data